Nuveen
ACAD icon

Nuveen’s Acadia Pharmaceuticals ACAD Stock Holding History

Nuveen’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-51,500
Closed -$1K – 3351
2021
Q1 		$1K Buy
+51,500
New +$2.27M ﹤0.01% 3358
2020
Q4 		– Sell
-61,200
Closed -$3K – 3303
2020
Q3 		$3K Buy
+61,200
New +$2.64M ﹤0.01% 3277

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen's ACAD Position: Q2 2026 in Review

Nuveen increased its Acadia Pharmaceuticals (ACAD) stake by 30% in Q2 2026, buying an estimated $6.85M and bringing the position to 1,348,192 shares worth $34.1M. The position accounts for 0.01% of the portfolio, ranked #933.

Nuveen first reported a position in ACAD in Q4 2013 and has held it in 34 quarters since. The position peaked at $94M in Q4 2019. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Nuveen held 1,348,192 shares of Acadia Pharmaceuticals worth $34.1M as of Q2 2026.
  • Nuveen bought 311,205 Acadia Pharmaceuticals shares in Q2 2026, an estimated $6.85M.
  • Acadia Pharmaceuticals made up 0.01% of Nuveen's portfolio in Q2 2026, its #933 holding.
  • Nuveen first reported a position in Acadia Pharmaceuticals in Q4 2013 and has held it in 34 quarters since.
  • Nuveen's Acadia Pharmaceuticals position peaked at $94M in Q4 2019.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.